BioSpace News Archive

MarkLogic Corporation, the next-generation data platform provider for simplifying data integration, together with eyeforpharma, a hub for senior-level pharma executives, patient advocacy groups and other health experts, released a report of gathered insights from pharmaceutical leaders on how data challenges and data sharing will impact the future of patient care and healthcare costs.

Technavio has announced its latest market research report titled global antihypertensive drugs market 2019-2023

Shenée Rayford oversees all aspects of Human Resources for the integrated health management provider, which promotes a unique culture devoted to “liberating” healthcare

LabCorp announced that it has provided notice of its intention to redeem all of its outstanding Zero Coupon Convertible Subordinated Notes due 2021 for cash on Dec. 19, 2019, in accordance with the terms of the Indenture, dated as of Oct. 23, 2006,, between LabCorp and The Bank of New York Mellon, as trustee and the conversion agent.

Enrollment Rate Exceeds Expectation, Suggesting High Unmet Need and Anticipation for Bermekimab in HS

North Bud Farms Inc. (CSE: NBUD) (OTCQB: NOBDF) (“NORTHBUD” or the “Company”) is pleased to announce that Bonfire Brands USA, a wholly owned subsidiary of NORTHBUD, has signed a definitive asset purchase agreement to acquire all assets of Nevada Botanical Science, Inc. (“NBS”) (see June 25, 2019 press release) in a transaction valued at USD$7.5 million.

More than 500 children undergo heart transplants in the U.S. each year, joining the thousands of children already living with a new heart, and while medical advancements have improved over the years, many of these children and their families still face a lifetime of challenges.

Kenai Spine, a regional spine center based in Alaska, is bringing the most advanced spine surgery capabilities to opposite sides of the planet, from Alaska to Africa.

Emerging research begins to identify neighborhood characteristics that could impact the incidence of and vulnerability to chronic disease

Met primary and secondary endpoints in non-small cell lung cancer (NSCLC) Phase II clinical trial in patients previously treated with chemotherapy (cohort A)